Drug updated on 9/4/2024
Dosage Form | Tablet (oral: 60 mg, 100 mg, 150 mg) |
Drug Class | Tetracycline class antibacterials |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ≥ 9 years of age.
Latest News
Summary
- Seysara (sarecycline) is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ≥ 9 years of age.
- This summary is based on the review of one systematic review/meta-analysis. [1]
- Sarecycline demonstrated effectiveness in treating both facial and truncal acne in a population of pediatric and adult acne patients (total n=226,019).
- Other tetracyclines (doxycycline, minocycline, tetracycline) were noted as effective for facial acne, with no specific data provided on their effectiveness for truncal acne.
- The study highlights that Sarecycline may have a broader range of effectiveness compared to the other tetracyclines, covering both facial and truncal acne.
- The safety outcomes highlighted differences in the ability of oral tetracyclines to minimize antibiotic resistance and gut dysbiosis, though specific numerical data are not provided.
- The study suggests that sarecycline, as a narrow-spectrum tetracycline, may have a different safety profile concerning antibiotic resistance and gut dysbiosis compared to other tetracyclines, but no specific comparative safety data or details on adverse effects are reported.
- The systematic review included both pediatric and adult acne patients (totaling 226,019 individuals); however, there were no specific subgroup considerations or relevant findings pertinent to distinct population types or subgroups mentioned in the study.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Seysara (sarecycline) Prescribing Information. | 2021 | Almirall LLC, Malvern, PA |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Oral tetracyclines and acne: a systematic review for dermatologists. | 2020 | Journal of Drugs in Dermatology |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Guidelines of care for the management of acne vulgaris. | 2024 | Journal of the American Academy of Dermatology |